

**CollPlant Holdings Ltd**  
("The Company")

June 15, 2017

Dear Sir or Madam,

**Re: Patent in USA**

The Company announces that the United States Patents Office has allowed an important patent for CollPlant Ltd, the wholly-owned subsidiary of the Company ("CollPlant"). The new patent expands the existing protection of CollPlant's basic technology including plant-based recombinant human collagen, inter alia, insofar as it is not limited to specific protein sequences in the plant.

The patent is wholly-owned by CollPlant and has been granted pursuant to the filing dated July 8, 2013, and is expected to expire in September 28, 2025. The patent is one of a range of approved patents that protect the Company's technology through until May 2029. For additional information concerning CollPlant's range of patents, see the 2016 Periodic Report, Chapter A, section 17.4 (which was published on Magna on March 28, 2017).

**About CollPlant**

CollPlant is a regenerative medicine company leveraging its proprietary, plant-based recombinant human collagen (rhCollagen) technology for the development and commercialization of tissue repair products, initially for the orthobiologics, 3D Bio-printing of tissue and organs, and advanced wound care markets. The Company's cutting-edge technology is designed to generate and process proprietary rhCollagen, among other patent-protected recombinant proteins. Given that CollPlant's rhCollagen is identical to the type I collagen produced by the human body, it offers significant advantages compared to currently marketed tissue-derived collagen, including improved biofunctionality, superior homogeneity and reduced risk of immune response. The Company's broad development pipeline includes biomaterials indicated for orthopedics and advanced wound healing. Lead products include: Vergenix<sup>®</sup>STR (Soft Tissue Repair Matrix), for the treatment of tendinopathy; and Vergenix<sup>®</sup>FG (Flowable Gel) wound filler, for treatment of acute and chronic wounds. CollPlant's business strategy includes proprietary development and manufacture of tissue repair products and their commercialization and distribution, together with leading third parties, alongside alliances with leading companies for joint development, manufacture and marketing of additional products.

For more information about CollPlant, visit <http://www.collplant.com>

Yours sincerely,

CollPlant Holdings Ltd

**Signed on behalf of the Company by:**

Yehiel Tal, CEO

Eran Rotem, CFO